| 0.9688 0.129 (15.33%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.18 | 1-year : | 1.31 |
| Resists | First : | 1.01 | Second : | 1.12 |
| Pivot price | 0.91  |
|||
| Supports | First : | 0.82 | Second : | 0.68 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 0.94 |
| MA(100) : | 1.05 |
MA(250) : | 1.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.8 |
D(3) : | 23.5 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 2.56 | Low : | 0.82 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TCRX ] has closed below upper band by 23.0%. Bollinger Bands are 27.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.97 - 0.98 | 0.98 - 0.98 |
| Low: | 0.83 - 0.83 | 0.83 - 0.84 |
| Close: | 0.96 - 0.97 | 0.97 - 0.98 |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Fri, 26 Jun 2026
Enterprise value to revenue forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
Fri, 26 Jun 2026
Price to earnings forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
Fri, 26 Jun 2026
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
Wed, 24 Jun 2026
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
Mon, 22 Jun 2026
TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial - Stock Titan
Mon, 22 Jun 2026
TScan Therapeutics Announces Positive Initial Data from - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 5.539e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 870 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2382e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 967.3 % |
| Return on Equity (ttm) | -29.7 % |
| Qtrly Rev. Growth | 9.14e+006 % |
| Gross Profit (p.s.) | -53.21 |
| Sales Per Share | -78.6 |
| EBITDA (p.s.) | -9.27476e+007 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -122 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.46 |
| Dividend | 0 |
| Forward Dividend | 934310 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|